The U.S. Army Medical Research and Development Command (USAMRDC) selected EIDB’s COVID vaccine candidate, Spike Ferritin Nanoparticle (SpFN), as one of the 2020 award recipients. This years’ award was jointly given to the Army-developed and patented adjuvant, Army Liposome Formulation with QS21 (ALFQ), which is used in the SpFN vaccine.
SpFN has shown promising results in preclinical studies and began Phase 1 clinical testing in April of 2021. ALFQ, which was awarded a patent in 2019, has shown to be strongly potent as a vaccine adjuvant in preclinical studies.
Congratulations to the team involved in the development of SpFN!